PTO/SB/8A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE and to a collection of information unless it contains valid OMB control number. Under the Paperwork Reduction Act of 1995, no deons are required to r Complete i Rnown Substitute for form 1449A/PTO & TRADEM! 09/645,455 **Application Number** INFORMATION DISCLOSURE Filing Date August 24,2000 Z STATEMENT BY APPLICANT First Named Inventor Group Art Unit 1633 (use as many sheets as necessary)

**Examiner Name** 

MS/DHR Sheet A-68344 of Attorney Docket Number **U.S. PATENT DOCUMENTS** Pages, Columns, Lines, Cite U.S. Patent Document Date of Publication of Examiner Name of Patentee or Applicant Where Relevant Cited Document Initials\* of Cited Document Kind Code<sup>2</sup> Passages or Relevant Number MM-DD-YYYY (if known) Figures Appear

						FOREIGN PATENT DOCUMEN	NTS		
Examiner Initials*	Cite No.	Kind Co		Ment Kind Code <sup>2</sup> (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
BL	BI	wo	95/33819	A	2	MITOTIX, INC.	12-1995		
	-B2	wo	00/14212	A	.1	MILLENNIUM PHARM., INC.	03-2000		
	B3	wo	00/15805	A	.1	SMITHKLINE BEECHAM	03-2000		
	- B4	wo	00/36124	A	2	CROPDESIGN N.V.	06-2000		
V	B5	wo	01/21799	A	.1	RIGEL PHARMACEUTICALS	03-2001		$oxed{oxed}$
									┷
									丄
			1	1			I		1

	 //			
Examiner Signature	sittle	Date Considered	3-15-02	·

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

lease type a p	plus sign (+) inside this b	$ox \rightarrow [$	HAL DAN	2 3 2002	O S Patent and Trac	Approved for use through 10/3 lemark Office: U.S. DEPART	1/2002.	OMB 0	(08-00) 551-0031	1
Inder the Pap	erwork Reduction Act of	f 1995, n	o person e re	uired to respo	odao a collection of information	unless it contains a valid OMI	3 control	number		_
Substi	tute for form 1449B	/РТО	Ety.	RADEMARK		Complete if Known	E		77	
	· · · · · · · · · · · · · · · · · · ·			HADEM	Application Number	09/645,456	$\overline{\pm}$			
INF	<b>ORMATIO</b>	ND	<b>ISCLOS</b>	URE	Filing Date	August 24, 2000	<u> </u>	AN	$\overline{}$	•
STA	TEMENT I	BY A	<b>APPLIC</b>	ANT	First Named Inventor	FU, C. Alan	Ħ	20	H	•
					Group Art Unit	1633	20	တ		•
	(use as many sh	eets as	necessary)		Examiner Name		8	20	<	
Sheet	2	of	2		Attorney Docket Number	A-68344-3/RMS/DHR	Q	2	Ш	•

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
BL	Cl	FU, et al., "TNIK, a Novel Member of the Germinal Center Kinase Family That Activates the c-Jun N-terminal Kinase Pathway and Regulates the Cytoskeleton," <i>J Biol Chem</i> 274(43):30729-30737 (1999)	
ĺ	C2	KITAMURA, et al., "Molecular Cloning of p125 <sup>NAP1</sup> , a Protein That Associates with an SH3 Domain of Nck," Biochem Biophys Res Comm 219:509-514 (1996)	
	C3	NAGASE et al., "Prediction of the Coding Sequences of Unidentified Human Genes. IX. The Complete Sequences of 100 New cDNA Clones from Brain Which Can Code for Large Proteins in vitro," DNA Research 5:31-39 (1998)	T
	C4	ROTHE et al., "I-TRAF is a novel TRAF-interacting protein that regulates TRAF-mediated signal transduction," Proc. Natl. Acad. Sci. USA 93:8241-8246 (Aug. 1996)	
	C5	SHI et al., "TNF-Mediated Activation of the Stress-Activated Protein Kinase Pathway: TNF Receptor-Associated Factor 2 Recruits and Activates Germinal Center Kinase Related," <i>J Immunol</i> 163:3279-3285 (Sep 1999)	
	C6	SUZUKI et al., "Down-regulation of the INK4 Family of Cyclin-Dependent Kinase Inhibitors by Tax Protein of HTLV-1 through Two Distinct Mechanisms," Virology 259:384-391 (1999)	
V	C7	OHARA, O. et al., GenBank Accession No. AB011123, 10-April-1998	
		·	
	·		

Examiner Signature	(1)0	ull	Date Considered	3-15-02	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Language Translation is attached.

OII	N/PER	BRIM	 IATION DI	SCLOS	IIRE	ATTY. DOCKET NO. A-68344-3/RMS/DHI	R		IAL NO. 645,456		
MAY 1 8 2000			ČITATIO		ONL	APPLICANT FU, Alan C.					
2001		DI 33	PTO-1449			FILING DATE August 24, 2000		GRC 163			
X PAI	DEMAS	<b>5</b> 2			U.S. PA	ATENT DOCUMENTS					
EXAMINE	EXAMINER'S INITIALS		PATENT NO.	DATE		NAME	CLAS		SUBCLASS	作ILING DATE	
							<del> </del>				
						4.4			DEC		`
										EIVE	J
									MAY	2 1 2001	
									TECH CEN	TER 1600/29	100
										8 5 5 5 5	
					FOREIGN	PATENT DOCUMENT	S				
EXAMINE INITIAL			PATENT NO.	DATE		COUNTRY	CI	ASS	SUBCLAS	Transl	
									S	Yes	No
		0	THER DOCL	IMENTS (	Including	, Author, Title, Da	te, Po	ertin	ent Pages	s, Etc.)	
m	_	1	Herskowitz,	'MAP Kina	ase Pathwa	ys in Yeast: For Mati	ing an	d Mo	ore," <i>Cell</i> , 8	80:187-197 (	(1995).
		2	Bagrodia et al., "Cdc42 and PAK-mediated Signaling Leads to Jun Kinase and p38 Mitogen-activated Protein Kinase Activation", <i>J. Biol. Chem.</i> , 270:27995-27998 (1995).							ed Protein	
		3	Kyriakis et al., "Sounding the Alarm: Protein Kinase Cascades Activated by Stress and Inflammation", <i>J. Biol. Chem.</i> , 271:24313-24316 (1996).							n", <i>J. Biol.</i>	
,		4	Ip et al., "Signal transduction by the c-Jun N-terminal kinase (JNK) – from inflammation to development", <i>Curr. Opin. Cell Biol.</i> , 10:205:219 (1998).							ment",	
		5	Sells et al., "Human p21-activated kinase (Pak1) regulates actin organization in mammalian cells", <i>Curr. Biol.</i> , 7:202-210 (1997).							Curr.	
V		6 Kyriakis, J., "Signaling by the Germinal Center Kinase Family of Protein Kinases", <i>J. Biol. Chem.</i> , 274:5259-5262 (1999).							74:5259-		
EXAMIN	NER	(	Jos AL	2	[	DATE CONSIDERED	3-	15 .	.02		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
8085 1449A.FRM (8/95) 1051515

, - F <sup>4</sup>										
OTNEO	RM	ATION DISCLOSURE	ATTY. DOCKET NO. A-68344-3/RMS/DHR	SERIAL NO. 09/645,456						
0176	હ્યું	CITATION	APPLICANT FU, Alan C.							
MAY 1 8 2001	₹ 88)	PTO-1449	FILING DATE August 24, 2000	GROUP 1633						
(4)	ÿ	OTHER DOCUMENTS (Including		ent Pages, Etc.)						
PU	7	Pombo et al., "Activation of the SAPK pa Nature, 377:750:754 (1995).	athway by the human STE20	) homologue germinal centre kinase",						
	Shi et al., "Activation of Stress-activated Protein Kinase/c-Jun N-terminal Kinase, but not NF-κB, by Tumor Necrosis Factor (TNF) Receptor 1 through a TNF Receptor-associated Factor 2- and Gern Center Kinase Related-dependent Pathway", J. Biol. Chem., 272:32102-32107 (1997).									
	9	Kiefer et al., "HPK1, a hematopoietic pro 7025 (1996).	otein kinase activating the SA	APK/JNK pathway", <i>EMBO J.</i> , 15:7013-						
	10	Diener et al, "Activation of the c-Jun N-t germinal center kinase", <i>Proc. Natl. Aca</i>	erminal kinase pathway by a ad. Sci. USA, 94:9687-9692	novel protein kinase related to human (1997).						
	11	Yao et al., "A Novel Human STE20-rela terminal Kinase Signaling Pathway", <i>J. I</i>								
	12	Su et al., "NIK is a new Ste20-related kin cascade via a conserved regulatory don								
	13	Yuasa et al., "Tumor Necrosis Factor Si Kinase (JNK) and p38", <i>J. Biol. Chem.</i> ,		Protein Kinase (SAPK)/Jun NH <sub>2</sub> -terminal						
	14		cloning of a <i>Dictyostelium</i> Ste20-like Protein Kinase That n Severin", <i>J. Biol. Chem.</i> , 273:12952-12959 (1998).							
				RECEIVED						
				MAY 2 1 2001						
				TECH CENTER 1600/2900						
,				1EOH OENTER 1800/2900						
ţ.										
<u> </u>										
EXAMINER		had all	ATE CONSIDERED 3-	15-02						